Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-10-03
2006-10-03
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C435S320100
Reexamination Certificate
active
07115257
ABSTRACT:
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
REFERENCES:
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 4968733 (1990-11-01), Muller et al.
patent: 4976859 (1990-12-01), Wechs
patent: 5106627 (1992-04-01), Aebischer et al.
patent: 5156844 (1992-10-01), Aebischer et al.
patent: 5158881 (1992-10-01), Aebischer et al.
patent: 5283187 (1994-02-01), Aebischer et al.
patent: 5284761 (1994-02-01), Aebischer et al.
patent: 5512600 (1996-04-01), Mikos et al.
patent: 5550050 (1996-08-01), Holland et al.
patent: 5554148 (1996-09-01), Aebischer et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5639275 (1997-06-01), Baetge et al.
patent: 5653687 (1997-08-01), Mills et al.
patent: 5653975 (1997-08-01), Baetge et al.
patent: 6361771 (2002-03-01), Tao et al.
patent: WO 92/19195 (1992-11-01), None
patent: WO 93/06222 (1993-04-01), None
patent: WO 94/01139 (1994-01-01), None
patent: WO 95/05452 (1995-02-01), None
patent: WO 97/34586 (1997-09-01), None
patent: WO 97/44065 (1997-11-01), None
patent: WO 98/05304 (1998-02-01), None
patent: WO 98/40498 (1998-09-01), None
patent: WO 99/52573 (1999-10-01), None
Aframian et al. Tissue Engineering; 8(4):649-659 (2002).
Airaksinen and Saarma. Nature Reviews, Neuroscience; 3:383-394 (May 2002).
Anderson, WF. Nature; 392 (Supp): 25-30 (Apr. 1998).
Kmiec, EB. American Scientist; 87:240-247 (May 1999).
Verma and Somla. Nature; 389:239242 (Sep. 1997).
Yuen, EC. Physical Med. Rebab. Clin. N. Amer.; 12(2):293-306 (May 2001).
Tao et al. Invest. Ophthal. Vis. Sci. 2002; 43(10):3292-3298.
Aebischer et al. (1996).Nature Medicine 2(6): 696-699.
Aebischer et al. (1991).Developmental Neurology 111: 269-275.
American Type Culture Collection Web page <http://phage.atcc.org> (ATCC No. CRL-2302).
Cayouette et al. (1998).J. Neurosci. 18(22): 9282-9293.
Dunn et al. (1998).Invest. Ophthalmol. Vis. Sci. 39(13): 2744-2749.
Dunn et al. (1996).Exp. Eye Res. 62: 155-169.
Emerich et al. (1996).J. Neurosci. 16(16): 5168-5181.
Finnemann et al. (1997).Proc. Natl. Acad. Sci. USA 94: 12932-12937.
Handa et al. (1998).Exp. Eye. Res. 66: 411-419.
Holtkamp et al. (1998).Clin. Exp. Immunol. 112: 34-43.
Maidji et al. (1996).J. Virol. 70(12): 8402-8410.
Pochon, et al. (1996).Human Gene Therapy 7: 851-860.
PCT. International Search Report for US 00/09150. Issued on Nov. 13, 2001.
Dean Brenda J.
Goddard Moses B. I.
Rein David H.
Stabila Paul F.
Tao Weng
Elrifi Ivor R.
Guzo David
Makar Kimberly A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Neurotech S.A.
LandOfFree
ARPE-19 as a platform cell line for encapsulated cell-based... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ARPE-19 as a platform cell line for encapsulated cell-based..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ARPE-19 as a platform cell line for encapsulated cell-based... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708828